Patent ID: 11857610
Assignee: CSL BEHRING AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of reducing the risk of onset of acute graft versus host disease (aGVHD) in a subject receiving hematopoietic cell transplantation (HCT) comprising administering alpha-1 antitrypsin (A1AT) according to the following schedule:
(a) administering a dose of 180 mg/kg A1AT to the subject one day prior to an HCT procedure; and
(b) administering a dose of 120 mg/kg A1AT to the subject twice weekly following HCT for at least 4 weeks optionally followed by a dose of 120 mg/kg A1AT at least once weekly for at least an additional 4 weeks;
optionally in combination with at least one immunosuppressive agent,
wherein the treatment reduces the risk of onset of chronic graft versus host disease (cGvHD) in the subject.